Upstream / Downstream
Explore pathways related to this product.
Important Ordering DetailsCustom Ordering Details: This product is assembled upon order. Please allow up to three weeks for your product to be processed
Pricing & Additional Information
To learn more about our Blocking Peptides, including pricing, please answer a few questions.
Find answers on our FAQs page.
PTM information and tools available.
Phospho-HER2/ErbB2 (Tyr1221/1222) Blocking Peptide #1254
Gallery: Phospho-HER2/ErbB2 (Tyr1221/1222) Blocking Peptide #1254
This peptide is used to block Phospho-HER2/ErbB2 (Tyr1221/1222) (6B12) Rabbit mAb #2243 reactivity.
The quality of the peptide was evaluated by reverse-phase HPLC and by mass spectrometry. The peptide blocks Phospho-HER2/ErbB2 (Tyr1221/1222) (6B12) Rabbit mAb # 2243 signal in immunohistochemistry.
Use as a blocking reagent to evaluate the specificity of antibody reactivity in immunohistochemistry protocols. For Immunohistochemistry, add twice the volume of peptide as volume of antibody used in a 100 ul total volume. Incubate for a minimum of 30 minutes prior to adding the entire volume to the slide. Recommended antibody dilutions can be found on the Phospho HER2/ErbB2 (Tyr 1221/1222)(6B12) Rabbit mAb #2243 data sheet.Storage: Supplied in 20 mM potassium phosphate (pH 7.0), 50 mM NaCl, 0.1 mM EDTA, 1 mg/ml BSA and 5% glycerol. Store at –20°C.
The ErbB2 (HER2) proto-oncogene encodes a 185 kDa transmembrane, receptor-like glycoprotein with intrinsic tyrosine kinase activity (1). While ErbB2 lacks an identified ligand, ErbB2 kinase activity can be activated in the absence of a ligand when overexpressed and through heteromeric associations with other ErbB family members (2). Amplification of the ErbB2 gene and overexpression of its product are detected in almost 40% of human breast cancers (3). Binding of the c-Cbl ubiquitin ligase to ErbB2 at Tyr1112 leads to ErbB2 poly-ubiquitination and enhances degradation of this kinase (4). ErbB2 is a key therapeutic target in the treatment of breast cancer and other carcinomas and targeting the regulation of ErbB2 degradation by the c-Cbl-regulated proteolytic pathway is one potential therapeutic strategy. Phosphorylation of the kinase domain residue Tyr877 of ErbB2 (homologous to Tyr416 of pp60c-Src) may be involved in regulating ErbB2 biological activity. The major autophosphorylation sites in ErbB2 are Tyr1248 and Tyr1221/1222; phosphorylation of these sites couples ErbB2 to the Ras-Raf-MAP kinase signal transduction pathway (1,5).
For Research Use Only. Not For Use In Diagnostic Procedures. Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.